A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
- Conditions
- Bladder Cancer
- Interventions
- Registration Number
- NCT05714202
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
- Detailed Description
Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG. The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total duration of the study will be up to 5 years and 2 months. Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the study.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1135
- Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ [CIS]), in participants who are Bacillus Calmette Guérin (BCG)-naïve
- BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
- All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma [HGUC]) for patients with papillary only disease (without CIS)
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to date of randomization
- Participants must be willing to undergo all study procedures
- Presence or history of histologically confirmed, muscle invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to [>=] T2)
- Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to randomization
- Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. Participants with tumors involving the prostatic urethra in men will be excluded
- A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (mL)
- Indwelling catheters are not permitted; however, intermittent catheterization is acceptable
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment Group A: TAR-200 + Cetrelimab Cetrelimab Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab. Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture BCG Vesiculture Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance). Treatment Group C: TAR-200 Alone TAR-200 Participants will receive intravesical TAR-200 alone once Q3W. Treatment Group A: TAR-200 + Cetrelimab TAR-200 Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab.
- Primary Outcome Measures
Name Time Method Event-free Survival (EFS) Up to 5 years 2 months EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to \[\>=\] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first.
- Secondary Outcome Measures
Name Time Method Overall Complete Response (CR) Rate Up to 5 years 2 months Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months.
Duration of CR Up to 5 years 2 months Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR.
Recurrence-Free Survival (RFS) Up to 5 years 2 months RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first.
Time to Progression (TTP) Up to 5 years 2 months TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first.
Overall Survival (OS) Up to 5 years 2 months OS is defined as the time from randomization to death, due to any cause.
Cancer Specific Survival (CSS) Up to 5 years 2 months CSS is defined as the time from randomization to the date of death due to bladder cancer.
Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE) Up to 5 years 2 months Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event.
Number of Participants with Adverse Events (AEs) Up to 5 years 2 months Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
Number of Participants with Change from Baseline in Laboratory Abnormalities Up to 5 years 2 months Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event.
Number of Participants with Change from Baseline in Vital Signs Abnormalities Up to 5 years 2 months Number of participants with change from baseline in vital signs (blood pressure \[systolic and diastolic\], heart rate, temperature, and weight) abnormalities will be reported.
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24 Up to 5 years 2 months EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).
Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores Up to 5 years 2 months EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).
Trial Locations
- Locations (240)
Polyclinique Bordeaux Nord Acquitaine
🇫🇷Bordeaux, France
CHU Gabriel-Montpied
🇫🇷Clermont-Ferrand, France
CHU Grenoble
🇫🇷Grenoble, France
Lahey Hospital & Medical Center
🇺🇸Burlington, Massachusetts, United States
Polyclinique de Limoges - Francois Chenieux
🇫🇷Limoges, France
Hospital Sao Rafael
🇧🇷Salvador, Brazil
CIMET s Inamdar Multispeciality Hospital
🇮🇳Pune, India
Uniwersytecki Szpital Kliniczny w Bialymstoku
🇵🇱Bialystok, Poland
Krajská nemocnice Liberec a.s.
🇨🇿Liberec, Czechia
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Fakultni nemocnice v Motole
🇨🇿Prague, Czechia
Mayo Clinic
🇺🇸Scottsdale, Arizona, United States
Arkansas Urology
🇺🇸Little Rock, Arkansas, United States
VA Long Beach Health Care System
🇺🇸Long Beach, California, United States
Genesis Research, LLC - West Coast Urology
🇺🇸Los Alamitos, California, United States
Cedars Sinai Medical Center
🇺🇸Los Angeles, California, United States
UC Davis Comprehensive Cancer Center
🇺🇸Sacramento, California, United States
Genesis Research
🇺🇸San Diego, California, United States
Providence Saint Johns Cancer Institute
🇺🇸Santa Monica, California, United States
Providence Medical Foundation
🇺🇸Santa Rosa, California, United States
Colorado Clinical Research
🇺🇸Lakewood, Colorado, United States
Urological Research Network
🇺🇸Hialeah, Florida, United States
Orlando Health Cancer Institute
🇺🇸Orlando, Florida, United States
Sarasota Memorial Hospital
🇺🇸Sarasota, Florida, United States
Grady Memorial Hospital
🇺🇸Atlanta, Georgia, United States
The Emory Clinic Department of Urology
🇺🇸Atlanta, Georgia, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Duly Health and Care
🇺🇸Lisle, Illinois, United States
Blessing Hospital
🇺🇸Quincy, Illinois, United States
Urology of Indiana
🇺🇸Carmel, Indiana, United States
First Urology
🇺🇸Jeffersonville, Indiana, United States
AMR Kansas City Oncology
🇺🇸Merriam, Kansas, United States
Wichita Urology Group
🇺🇸Wichita, Kansas, United States
Chesapeake Urology Research Associates
🇺🇸Hanover, Maryland, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
University Of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Mayo Clinic Rochester
🇺🇸Rochester, Minnesota, United States
The Urology Center, PC
🇺🇸Omaha, Nebraska, United States
Cooper Health System MD Anderson Cancer Center at Cooper
🇺🇸Camden, New Jersey, United States
VA NY Harbor Healthcare System
🇺🇸New York, New York, United States
Icahn School of Medicine at Mt. Sinai
🇺🇸New York, New York, United States
Associated Medical Professionals of Ny
🇺🇸Syracuse, New York, United States
SUNY Upstate Med Univ
🇺🇸Syracuse, New York, United States
Vidant Urology - Greenville
🇺🇸Greenville, North Carolina, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Central Ohio Urology Group
🇺🇸Gahanna, Ohio, United States
Centers for Advanced Urology LLC d b a MidLantic Urology
🇺🇸Bala-Cynwyd, Pennsylvania, United States
Thomas Jefferson University Hospital
🇺🇸Philadelphia, Pennsylvania, United States
UPMC Shadyside Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Carolina Urologic Research Center
🇺🇸Myrtle Beach, South Carolina, United States
Urology Associates
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Urology Austin
🇺🇸Austin, Texas, United States
Urology Clinics of North Texas
🇺🇸Dallas, Texas, United States
Houston Metro Urology
🇺🇸Houston, Texas, United States
Houston Methodist Hospital
🇺🇸Houston, Texas, United States
Urology San Antonio Research
🇺🇸San Antonio, Texas, United States
Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
George E. Wahlen VAMC
🇺🇸Salt Lake City, Utah, United States
Thomayerova nemocnice, Onkologicka klinika
🇨🇿Praha 4, Czechia
Urology Of Virginia, Pllc
🇺🇸Virginia Beach, Virginia, United States
Spokane Urology
🇺🇸Spokane, Washington, United States
Hospital Italiano de Buenos Aires
🇦🇷Buenos Aires, Argentina
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
🇦🇷Buenos Aires, Argentina
Centro Urologico Profesor Bengio
🇦🇷Cordoba, Argentina
Hospital Privado Centro Medico de Cordoba
🇦🇷Cordoba, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
🇦🇷Córdoba, Argentina
Hospital Privado de la Comunidad
🇦🇷Mar del Plata, Argentina
Instituto Medico Rio Cuarto
🇦🇷Rio Cuarto, Argentina
Austin Health
🇦🇺Heidelberg, Australia
Macquarie University Hospital
🇦🇺Macquarie University, Australia
Hollywood Private Hospital
🇦🇺Nedlands, Australia
Mater Hospital Brisbane
🇦🇺South Brisbane, Australia
ZNA Middelheim
🇧🇪Antwerpen, Belgium
AZ Sint-Jan
🇧🇪Brugge, Belgium
AZ Sint-Lucas
🇧🇪Brugge, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
UZ Gent
🇧🇪Gent, Belgium
Centre Hospitalier de l'Ardenne
🇧🇪Libramont-Chevigny, Belgium
AZ Delta
🇧🇪Roeselare, Belgium
Vitaz
🇧🇪Sint Niklaas, Belgium
GZA Ziekenhuizen- Campus St Augustinus
🇧🇪Wilrijk, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
NAIC Nair Antunes Instituto do Cancer
🇧🇷Bauru, Brazil
Universidade Estadual De Campinas
🇧🇷Campinas, Brazil
Liga Paranaense de Combate ao Cancer
🇧🇷Curitiba, Brazil
Liga Norte Riograndense Contra O Cancer
🇧🇷Natal, Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hospital Regional do Cancer - Hospital de Esperança
🇧🇷Presidente Prudente, Brazil
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha, Czechia
Hospital Ana Nery Santa Cruz do Sul
🇧🇷Santa Cruz Do Sul, Brazil
CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
🇧🇷Santo Andre, Brazil
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
🇧🇷Sao Paulo, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
🇧🇷Sao Paulo, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷São Paulo, Brazil
Nova Scotia Health Authority
🇨🇦Halifax, Nova Scotia, Canada
St Josephs Healthcare Hamilton
🇨🇦Hamilton, Ontario, Canada
Princess Margaret Cancer Centre University Health Network
🇨🇦Toronto, Ontario, Canada
CHUM - Centre hospitalier universitaire de Montreal
🇨🇦Montréal, Quebec, Canada
Unite de Recherche Clinique du CISSS des Laurentides
🇨🇦Saint Jerome Quebec, Quebec, Canada
CHU de Quebec Universite Laval Hopital de l Enfant Jesus
🇨🇦Quebec, Canada
Peking University First Hospital
🇨🇳Beijing, China
Beijing Hospital
🇨🇳Beijing, China
Beijing Luhe Hospital, Capital Medical University
🇨🇳Beijing, China
Hunan Province Cancer Hospital
🇨🇳Chang Sha, China
The First Bethune Hospital of Jilin University
🇨🇳Changchun, China
West China Hospital Sichuan University
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
People's Hospital of Deyang City
🇨🇳Deyang City, China
Sun Yat Sen University Cancer Center
🇨🇳GuangZhou, China
Zhejiang Provincial People's Hospital
🇨🇳Hangzhou, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Nanjing Drum Tower Hospital
🇨🇳Nanjing, China
The First Affiliated Hospital of Ningbo University
🇨🇳Ningbo, China
Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
🇨🇳Shanghai, China
Lister Hospital
🇬🇧Stevenage, United Kingdom
Huadong Hospital Affiliated to Fudan University
🇨🇳Shanghai, China
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
The Second Hospital Of Tianjin Medical University
🇨🇳Tianjin, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, China
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
🇨🇳Wuhan, China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
🇨🇳Xian, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Fakultni nemocnice u sv. Anny v Brne
🇨🇿Brno, Czechia
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Králové, Czechia
Hôpital Edouard Herriot
🇫🇷Lyon, France
CHU de Nantes hotel Dieu
🇫🇷Nantes, France
CHU Nimes
🇫🇷Nimes, France
Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
🇫🇷Orléans, France
Groupe Hospitalier Diaconesses Croix Saint Simon
🇫🇷PARIS cedex 20, France
Hôpital Universitaire Pitié-Salpêtrière
🇫🇷Paris, France
Hopital Europeen Georges-Pompidou
🇫🇷Paris, France
APHP - Hopital Bichat - Claude Bernard
🇫🇷Paris, France
Clinical La Croix Du Sud - Ramsay Santé
🇫🇷Quint-Fonsegrives, France
Chu Rennes Hopital Pontchaillou
🇫🇷Rennes, France
Institut de Cancerologie Strasbourg Europe ICANS
🇫🇷Strasbourg, France
CHU Rangueil
🇫🇷Toulouse, France
Urologicum Duisburg
🇩🇪Duisburg, Germany
Universitatsklinikum Erlangen
🇩🇪Erlangen, Germany
Universitatsklinikum Essen
🇩🇪Essen, Germany
Universitaetsklinikum Frankfurt
🇩🇪Frankfurt am Main, Germany
Universitaetsklinikum Freiburg
🇩🇪Freiburg, Germany
Urologische Partnerschaft Koln UPK
🇩🇪Köln, Germany
Matthias Schulze - Germany
🇩🇪Markkleeberg, Germany
Urologie Neandertal Praxis Mettmann
🇩🇪Mettmann, Germany
Universitatsklinikum Munster
🇩🇪Muenster, Germany
Klinikum rechts der Isar an der Technischen Universitat Munchen
🇩🇪München, Germany
Klinikum Nurnberg Nord
🇩🇪Nuernberg, Germany
Medizinisches Versorgungszentrum - Urologie
🇩🇪Nurnberg, Germany
Studienpraxis Urologie Nurtingen
🇩🇪Nürtingen, Germany
Caritas-Krankenhaus St. Josef
🇩🇪Regensburg, Germany
Universitat Tubingen
🇩🇪Tübingen, Germany
Health Care Global Enterprises pvt Ltd
🇮🇳Bangalore, India
Post Graduate Institute of Medical Education And Research PGIMER
🇮🇳Chandigarh, India
Artemis Hospital
🇮🇳Gurugram, India
Netaji Subhas chandra Bose Cancer Research Institute
🇮🇳Kolkata, India
Tata Memorial Hospital
🇮🇳Mumbai, India
Generale Regionale F. Miulli
🇮🇹Acquaviva delle Fonti, Italy
Ospedale Cardinal Massaia
🇮🇹Asti, Italy
Ospedale San Giuseppe Moscati di Avellino
🇮🇹Avellino, Italy
Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale
🇮🇹Castelfranco Veneto, Italy
Ospedale San Raffaele di Milano
🇮🇹Milano, Italy
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Fondazione G Pascale Istituto Nazionale Tumori IRCCS
🇮🇹Napoli, Italy
Ospedale S. Maria Delle Croci
🇮🇹Ravenna, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Rome, Italy
Fuji City General Hospital
🇯🇵Fuji-shi, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Japan
Nara Medical University Hospital
🇯🇵Kashihara-shi, Japan
Kimitsu Chuo Hospital
🇯🇵Kisarazu-shi, Japan
Kobe City Medical Center General Hospital
🇯🇵Kobe City, Japan
National Hospital Organization Kumamoto Medical Center
🇯🇵Kumamoto shi, Japan
Nagano Municipal Hospital
🇯🇵Nagano-shi, Japan
Nagasaki University Hospital
🇯🇵Nagasaki-shi, Japan
JRC Nagasaki Genbaku Hospital
🇯🇵Nagasaki-Shi, Japan
Saiseikai Narashino Hospital
🇯🇵Narashino-shi, Japan
Ehime University Hospital
🇯🇵Toon-shi, Japan
Toyama University Hospital
🇯🇵Toyama-shi, Japan
Yamaguchi University Hospital
🇯🇵Ube, Japan
Yokohama City University Medical Center
🇯🇵Yokohama, Japan
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Chungbuk National University Hospital
🇰🇷Cheongju, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Keimyung University Dongsan Hospital
🇰🇷Daegu, Korea, Republic of
National Cancer Center
🇰🇷Gyeonggi-do, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Marys Hospital
🇰🇷Seoul, Korea, Republic of
Consultorio Medico dentro del Hospital Angeles Acoxpa
🇲🇽Ciudad de México, Mexico
Hospital Universitario Dr Jose Eleuterio Gonzalez
🇲🇽Monterrey, Mexico
Avix Investigacion Clinica S C
🇲🇽Monterrey, Mexico
Eme Red Hospitalaria
🇲🇽Mérida, Mexico
Oncologico Potosino
🇲🇽San Luis Potosí, Mexico
Spaarne Ziekenhuis
🇳🇱Hoofddorp, Netherlands
Canisius-Wilhelmina Ziekenhuis
🇳🇱Nijmegen, Netherlands
Radboud Umcn
🇳🇱Nijmegen, Netherlands
IN VIVO Sp. z o.o
🇵🇱Bydgoszcz, Poland
Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
🇵🇱Lublin, Poland
Centrum Medyczne
🇵🇱Piotrkow Trybunalski, Poland
Clinical Research Center sp z o o MEDIC R s k
🇵🇱Poznan, Poland
Wojewodzki Szpital Specjalistyczny im Janusza Korczaka
🇵🇱Slupsk, Poland
Provita Poliklinika
🇵🇱Warszawa, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
🇵🇱Wroclaw, Poland
Ipo Coimbra
🇵🇹Coimbra, Portugal
Uls Santa Maria - Hosp. Santa Maria
🇵🇹Lisboa, Portugal
Uls Gaia Espinho
🇵🇹Vila Nova de Gaia, Portugal
Hosp Univ A Coruna
🇪🇸A Coruña, Spain
Hosp. Punta de Europa
🇪🇸Algeciras, Spain
Fund. Puigvert
🇪🇸Barcelona, Spain
Hosp. Gral. Univ. de Castellon
🇪🇸Castellon, Spain
Hosp. Puerta Del Mar
🇪🇸Cádiz, Spain
Hosp. Univ. de Bellvitge
🇪🇸L'Hospitalet de Llobregat, Spain
Hosp. Univ. Lucus Augusti
🇪🇸Lugo, Spain
Clinica Univ. de Navarra
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp Virgen de La Victoria
🇪🇸Málaga, Spain
Hosp. Univ. Marques de Valdecilla
🇪🇸Santander, Spain
Hosp. Clinico Univ. de Valencia
🇪🇸Valencia, Spain
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung City, Taiwan
Chang Kung Memorial Hospital
🇨🇳Kaohsiung, Taiwan
China Medical University Hospital
🇨🇳Taichung City, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
🇨🇳Taoyuan, Taiwan
Western General Hospital
🇬🇧Edinburgh, United Kingdom
St Bartholomews Hospital
🇬🇧London, United Kingdom
The Royal Marsden NHS Trust
🇬🇧London, United Kingdom
Charing Cross Hospital
🇬🇧London, United Kingdom
Derriford Hospital
🇬🇧Plymouth, United Kingdom
Scunthorpe General Hospital
🇬🇧Scunthorpe, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
🇬🇧Sheffield, United Kingdom
Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
🇬🇧Truro, United Kingdom